Skip to main content

Table 4 Morbidity of newborns treated at the facility in two time periods

From: Improved referral and survival of newborns after scaling up of intensive care in Suriname

  Period 1 (N = 320)
(July 2014–March 2015)
Period 2 (N = 281)
(April 2015–December 2015)
Relative Risk
(95% CI)
P-value
N % N %
Respiratory morbidity BPD 4 1.3 10 3.6 2.85 (0.90–8.98) 0.07
VAP 9 2.8 5 1.8 0.63 (0.21–1.87) 0.41
Pneumothorax 4 1.3 7 2.5 1.99 (0.59–6.74) 0.27
NECa Total 10 13.5 12 21.4 1.59 (0.74–3.40) 0.24
  ≥ Stage 2 4 5.4 7 12.5 2.31 (0.71–7.51) 0.16
Sepsisb Total 96 30.0 109 38.8 1.29 (1.03–1.62) 0.02
 Positive blood culture 38 11.9 25 8.9 0.75 (0.46–1.20) 0.24
Positive ESBL culturec Total 34 10.6 39 13.9 1.31 (0.85–2.01) 0.22
Duration of stay (days)   Mean SD Mean SD   
13 16 14 18   0.44
  1. BPD bronchopulmonary dysplasia, VAP ventilator-associated pneumonia, NEC necrotizing enterocolitis, ESBL extended spectrum beta-lactamase
  2. aCalculated for newborns with a birthweight below 1500 g (N = 74 and N = 56 in period 1 and period 2, respectively)
  3. bIncludes: early and late-onset clinical (i.e., high clinical suspicion, treated with antibiotics for 7 days; raised C-reactive protein levels) and blood culture positive sepsis
  4. cIncludes: blood and urine cultures and cultures on (tracheal aspirate, skin and anal) swabs, central lines or ventilation tubes